摘要
目前,艾滋病病毒(HIV)疫苗的研究进展缓慢,暴露前预防(Pr EP)HIV感染在高危人群中的效果已被多项临床试验研究证实,世界卫生组织(WHO)和美国疾病预防控制中心(CDC)均公布了Pr EP作为一项新的HIV干预措施用药指南,旨在降低高危人群HIV新发感染率。而Pr EP作为一项公共政策推广,需要了解其成本效益情况。该文对Pr EP的卫生经济学评价情况作一综述。
At present,the research progress of vaccine for human immunodeficiency virus（ HIV） prevention has developed slowly. Pre-exposure prophylaxis（ Pr EP） has been proved by a number of clinical trials to be effective for prevention of HIV infection in high-risk populations. World Health Organization（ WHO） and the Centers for Disease Control and Prevention of USA announced a clinical practice guideline that Pr EP was taken as a new HIV intervention measure to the high-risk populations to reduce the rate of new HIV infections. Because Pr EP becomes a public policy that needs to be extended,its cost-effectiveness must be known. The health economic evaluation of Pr EP is reviewed in this paper.
出处
《中国临床新医学》
2017年第7期703-707,共5页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
广西艾滋病防治研究重点实验室开放课题基金项目(编号:gklapt201604)
广西卫计委科研课题(编号:Z2014625
Z2016448)
广西壮族自治区疾病预防控制中心科技创新课题(编号:GXCDCCK-011)
关键词
暴露前预防
艾滋病病毒
卫生经济学评价
Pre-exposure prophylaxis（PrEP）
Human immunodeficiency virus（HIV）
Health economics evaluation
